Skip to content

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

  • Home
  • Infectious Disease
  • Metabolic
  • Neurological
  • Nutrition
  • Public Health

DAILYZ HEALTH NEWS

ALL ABOUT DAILYZ HEALTH NEWS

  • Home
  • Infectious Disease
  • Metabolic
  • Neurological
  • Nutrition
  • Public Health
Health

Servier presents four-year results from Phase 2 FIREFLY-1 study of OJEMDA in pediatric low-grade glioma at SNO 2026

November 16, 2026 Evan Vega

Servier presents four-year FIREFLY-1 data: OJEMDA shows 50.9-month median time to next treatment in pediatric low-grade glioma.

US loses measles elimination
Health

US loses measles elimination status after 26 years as historic resurgence sickens thousands

November 15, 2026 Evan Vega
Measles cases top 5,000
Health

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

November 9, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega
Infant bleeding episodes jump
Health

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

November 8, 2026 Evan Vega
Health

Servier presents four-year results from Phase 2 FIREFLY-1 study of OJEMDA in pediatric low-grade glioma at SNO 2026

November 16, 2026 Evan Vega

Servier presents four-year FIREFLY-1 data: OJEMDA shows 50.9-month median time to next treatment in pediatric low-grade glioma.

US loses measles elimination
Health

US loses measles elimination status after 26 years as historic resurgence sickens thousands

November 15, 2026 Evan Vega
Measles cases top 5,000
Health

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

November 9, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega
Health

Servier presents four-year results from Phase 2 FIREFLY-1 study of OJEMDA in pediatric low-grade glioma at SNO 2026

November 16, 2026 Evan Vega

Servier presents four-year FIREFLY-1 data: OJEMDA shows 50.9-month median time to next treatment in pediatric low-grade glioma.

US loses measles elimination
Health

US loses measles elimination status after 26 years as historic resurgence sickens thousands

November 15, 2026 Evan Vega
Measles cases top 5,000
Health

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

November 9, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega
Infant bleeding episodes jump
Health

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

November 8, 2026 Evan Vega
Health

Servier presents four-year results from Phase 2 FIREFLY-1 study of OJEMDA in pediatric low-grade glioma at SNO 2026

November 16, 2026 Evan Vega

Servier presents four-year FIREFLY-1 data: OJEMDA shows 50.9-month median time to next treatment in pediatric low-grade glioma.

US loses measles elimination
Health

US loses measles elimination status after 26 years as historic resurgence sickens thousands

November 15, 2026 Evan Vega
Measles cases top 5,000
Health

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

November 9, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega
Health

Servier presents four-year results from Phase 2 FIREFLY-1 study of OJEMDA in pediatric low-grade glioma at SNO 2026

November 16, 2026 Evan Vega

Servier presents four-year FIREFLY-1 data: OJEMDA shows 50.9-month median time to next treatment in pediatric low-grade glioma.

US loses measles elimination
Health

US loses measles elimination status after 26 years as historic resurgence sickens thousands

November 15, 2026 Evan Vega
Measles cases top 5,000
Health

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

November 9, 2026 Evan Vega
Lp(a) reduction, neutral outcome
Health

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

November 8, 2026 Evan Vega
Infant bleeding episodes jump
Health

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

November 8, 2026 Evan Vega
Health
November 16, 2026 Evan Vega

Servier presents four-year results from Phase 2 FIREFLY-1 study of OJEMDA in pediatric low-grade glioma at SNO 2026

Servier presents four-year FIREFLY-1 data: OJEMDA shows 50.9-month median time to next treatment in pediatric low-grade glioma.

Read More
US loses measles elimination
Health
November 15, 2026 Evan Vega

US loses measles elimination status after 26 years as historic resurgence sickens thousands

US loses measles elimination status after 26 years; PAHO cites 12-month transmission and 5,400+ cases in 2026.

Read More
Measles cases top 5,000
Health
November 9, 2026 Evan Vega

Measles Cases Top 5,000 in U.S. for First Time in 35 Years as Death Toll Rises

CDC reports 5,182 measles cases in US, highest since 1991, with 8 deaths; 96% of cases among unvaccinated or unknown status.

Read More
Lp(a) reduction, neutral outcome
Health
November 8, 2026 Evan Vega

Lp(a) HORIZON Trial: Lp(a) Fell by 78%, but Cardiovascular Outcomes Unexpectedly Neutral

Lp(a) reduced 78% with pelacarsen, but cardiovascular outcomes showed no benefit in HORIZON trial.

Read More
Infant bleeding episodes jump
Health
November 8, 2026 Evan Vega

U.S. Infant Bleeding Episodes Jump as Vitamin K Refusals Rise, Two Studies Find

U.S. infant bleeding episodes rise as vitamin K shot refusals grow; rate fell from 97.7% to 95% (2017-2025) amid declining trust.

Read More
Amivantamab approved for HNSCC
Health
November 7, 2026 Evan Vega

FDA Grants Accelerated Approval to Amivantamab and Hyaluronidase for Previously Treated HNSCC

FDA grants accelerated approval to amivantamab/hyaluronidase for recurrent/metastatic HNSCC after platinum and PD-1/PD-L1 therapy, based on 42% ORR.

Read More
FDA approves Rybrevant Faspro
Health
November 7, 2026 Evan Vega

FDA Approves Rybrevant Faspro for Advanced Head and Neck Cancer

FDA grants accelerated approval to Rybrevant Faspro for adults with recurrent or metastatic head and neck squamous cell carcinoma.

Read More
FDA Approves Pirtobrutinib Treatment
Health
October 4, 2026 Evan Vega

FDA Approves Pirtobrutinib for Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

The FDA approved pirtobrutinib for untreated chronic lymphocytic leukemia and small lymphocytic lymphoma without 17p deletion.

Read More
HHS Expands Mental Health
Health
October 4, 2026 Evan Vega

HHS Awards Nearly $250 Million to Expand Mental Health and Addiction Treatment Services

The U.S. HHS awarded $247.9 million in grants to expand mental health and addiction treatment services nationwide.

Read More
Ebola Worker Evacuated Congo
Health
October 3, 2026 Evan Vega

Doctors Without Borders Worker Evacuated After Contracting Ebola in Democratic Republic of Congo Outbreak

A Doctors Without Borders worker infected with Bundibugyo virus during DRC Ebola outbreak was evacuated to the Netherlands for specialized treatment.

Read More
  • ← Previous
Copyright © 2026 DAILYZ HEALTH NEWS. Powered by ColorMag and WordPress.